These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 2396472)

  • 21. [Epidemiologic study of measles, rubella and mumps with regard to the possibility of their control by immunization].
    Rodríguez Borrego MJ; García León J; Bolumar F; Nájera E
    Rev Sanid Hig Publica (Madr); 1985; 59(1-2):117-25. PubMed ID: 4059834
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs.
    Dourado I; Cunha S; Teixeira MG; Farrington CP; Melo A; Lucena R; Barreto ML
    Am J Epidemiol; 2000 Mar; 151(5):524-30. PubMed ID: 10707922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland.
    Peltola H; Karanko V; Kurki T; Hukkanen V; Virtanen M; Penttinen K; Nissinen M; Heinonen OP
    Lancet; 1986 Jan; 1(8473):137-9. PubMed ID: 2867355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mumps meningitis following measles, mumps, and rubella immunisation.
    Lancet; 1989 Aug; 2(8659):394-5. PubMed ID: 2569586
    [No Abstract]   [Full Text] [Related]  

  • 27. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P; Gabutti G; Giammanco G; Dentico P; Moiraghi AR; Ponzio F; Soncini R
    Vaccine; 2000 Jun; 18(25):2796-803. PubMed ID: 10812221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sentinel surveillance shows small decline in MMR coverage.
    Commun Dis Rep CDR Wkly; 1998 Sep; 8(36):317, 320. PubMed ID: 9782644
    [No Abstract]   [Full Text] [Related]  

  • 29. Transmission of Urabe mumps vaccine between siblings.
    Sawada H; Yano S; Oka Y; Togashi T
    Lancet; 1993 Aug; 342(8867):371. PubMed ID: 8101611
    [No Abstract]   [Full Text] [Related]  

  • 30. Hemiplegia after measles, mumps, and rubella vaccination.
    Sackey AH; Broadhead RL
    BMJ; 1993 May; 306(6886):1169. PubMed ID: 8499819
    [No Abstract]   [Full Text] [Related]  

  • 31. Measles and mumps immunization: benefit versus risk factors.
    Krugman S
    Dev Biol Stand; 1979; 43():253-7. PubMed ID: 520672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.
    Perez-Vilar S; Weibel D; Sturkenboom M; Black S; Maure C; Castro JL; Bravo-Alcántara P; Dodd CN; Romio SA; de Ridder M; Nakato S; Molina-León HF; Elango V; Zuber PLF;
    Vaccine; 2018 Jan; 36(3):347-354. PubMed ID: 28558983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surveillance of symptoms following MMR vaccine in children.
    Miller C; Miller E; Rowe K; Bowie C; Judd M; Walker D
    Practitioner; 1989 Jan; 233(1461):69-73. PubMed ID: 2798288
    [No Abstract]   [Full Text] [Related]  

  • 35. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies.
    Stokes J; Weibel RE; Villarejos VM; Arguedas JA; Buynak EB; Hilleman MR
    JAMA; 1971 Oct; 218(1):57-61. PubMed ID: 4937795
    [No Abstract]   [Full Text] [Related]  

  • 38. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines.
    Farrington P; Pugh S; Colville A; Flower A; Nash J; Morgan-Capner P; Rush M; Miller E
    Lancet; 1995 Mar; 345(8949):567-9. PubMed ID: 7619183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute idiopathic thrombocytopenic purpura following combined vaccination against measles, mumps, and rubella.
    Chang SK; Farrell DL; Dougan K; Kobayashi B
    J Am Board Fam Pract; 1996; 9(1):53-5. PubMed ID: 8770810
    [No Abstract]   [Full Text] [Related]  

  • 40. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
    Janaszek-Seydlitz W; Bucholc B; Wysokińska T; Górska P; Gniadek G
    Przegl Epidemiol; 2003; 57(2):281-8. PubMed ID: 12910596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.